Helena Tayton-Martin
Founder at ADAPTIMMUNE THERAPEUTICS PLC
Net worth: 474 102 $ as of 2024-03-30
Helena Tayton-Martin active positions
Companies | Position | Start | End |
---|---|---|---|
ADAPTIMMUNE THERAPEUTICS PLC | Corporate Officer/Principal | 2017-03-14 | - |
Founder | 2007-12-31 | - | |
Chief Operating Officer | 2007-12-31 | 2017-03-14 | |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Director/Board Member | - | - |
Chief Operating Officer | 2009-09-16 | - | |
Founder | 2007-12-31 | - | |
Adaptimmune LLC
Adaptimmune LLC Medical/Nursing ServicesHealth Services Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a private company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA. | President | - | - |
Corporate Secretary | - | - |
Career history of Helena Tayton-Martin
Former positions of Helena Tayton-Martin
Companies | Position | Start | End |
---|---|---|---|
TRILLIUM THERAPEUTICS | Director/Board Member | 2017-09-30 | 2021-11-16 |
Independent Dir/Board Member | 2017-09-30 | 2021-11-16 | |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Chief Operating Officer | 2007-12-31 | 2016-12-31 |
Founder | 2007-12-31 | 2016-12-31 | |
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Corporate Officer/Principal | - | - |
Training of Helena Tayton-Martin
University of Bristol | Doctorate Degree |
London Business School | Masters Business Admin |
Statistics
International
United Kingdom | 6 |
United States | 3 |
Canada | 2 |
Operational
Chief Operating Officer | 3 |
Founder | 3 |
Director/Board Member | 2 |
Sectoral
Health Technology | 5 |
Consumer Services | 3 |
Health Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
Private companies | 5 |
---|---|
Trillium Therapeutics ULC
Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
MediGene, Inc.
MediGene, Inc. Pharmaceuticals: MajorHealth Technology MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA. | Health Technology |
Avidex Ltd.
Avidex Ltd. Pharmaceuticals: MajorHealth Technology Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK | Health Technology |
Adaptimmune Ltd.
Adaptimmune Ltd. Medical/Nursing ServicesHealth Services Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom. | Health Services |
Adaptimmune LLC
Adaptimmune LLC Medical/Nursing ServicesHealth Services Part of Adaptimmune Therapeutics Plc, Adaptimmune LLC is a private company that focuses on the use of T cell therapy to treat cancer and infectious disease. The company is based in Philadelphia, PA. | Health Services |
- Stock Market
- Insiders
- Helena Tayton-Martin
- Experience